Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Medtronic, Inc. : Medtronic Announces FDA Approval and Launch of Its Advisa MRI Pacemaker System



 Medtronic, Inc. : Medtronic Announces FDA Approval and Launch of Its Advisa
                             MRI Pacemaker System

Medtronic, Inc.

Second-generation MR-Conditional Pacemaker Combines Advanced Pacing Technology
with MRI Access

MINNEAPOLIS - February 13, 2013 - Showcasing its leadership position in pacing
technologies, Medtronic, Inc. (NYSE: MDT), today announced the U.S. Food and
Drug Administration (FDA) approval and U.S. launch of its Advisa DR MRI(TM)
SureScan^®  pacing system. The Advisa MRI system is Medtronic's
second-generation MR-Conditional pacemaker and is the first system to combine
the most advanced pacing technology with proven MRI access.

MRI is the standard of care in soft tissue imaging, providing information not
seen with X-ray, ultrasound or CT scans, and is critical for early detection,
diagnosis and treatment. Advisa MRI was specifically tested and approved for
use as labeled with MRI scanners in the U.S. Of the 156 patients scanned in
the Advisa MRI Clinical Trial, none showed any MRI-related complications.  The
new system includes an Advisa MRI device and two CapSureFix MRI^(TM)
SureScan^® leads, which must be used together.

"Your physician can implant a pacemaker with advanced options that will allow
for broad access to MRI scanning," said Dr. J. Rod Gimbel of Cardiology
Associates of East Tennessee in Knoxville, Tenn. "MRI is just so very
important and traditional pacemakers not FDA approved for MRI scanning often
prevent the patient from having an MRI when they need it. With more than 85
percent of pacemaker patients being at least 65 years old and having multiple
comorbidities for which MRI may be needed, it's key that physicians and
patients have a pacing system that allows MRI imaging as a diagnostic
procedure."

The first SureScan pacemaker system was introduced in Europe in 2008 and its
use in the MRI environment is supported by clinical studies and extensive
computer modeling, as well as real-world data. To date, more than 100,000
Medtronic SureScan devices have been sold worldwide;^[1] and, in the U.S., it
is estimated that more than 10 percent of patients with SureScan pacing
systems have received MRIs.^[2] These patients received Medtronic's
first-generation Revo MRI^® SureScan^® pacing system, which was the only FDA
approved (February 2011) MR-Conditional pacemaker in the U.S. before the
Advisa MRI system.

Until the availability of Medtronic's SureScan pacing systems, patients with
pacemakers in the U.S. have been contraindicated from receiving MRI scans
because of potential interactions between the MRI and device function.
According to published literature, up to 75 percent of patients worldwide with
implanted cardiac devices are expected to need an MRI scan during the lifetime
of their devices.^[3]

Advisa MRI - Medtronic's MRI Pacing System with Innovative Technology
Medtronic's Advisa MRI pacing system provides physicians with innovative
technology that will benefit their patients, including the MVP^® (Managed
Ventricular Pacing) algorithm, which is proven to reduce unnecessary
ventricular pacing.^[4] Additional Advisa features include:

  * Complete automaticity with Ventricular and Atrial Capture Management(TM)
    (VCM and ACM) to eliminate manual threshold checks and extend longevity of
    the device by up to one year.^[5]
  * Diagnostics, such as the Cardiac Compass^® Report, and AF management tools
    that assist physicians in the early detection and treatment of atrial
    fibrillation.
  * Remote monitoring via Medtronic's CareLink^® Network, which transmits
    comprehensive arrhythmia and diagnostic device data to a physician's
    clinic.
  * Rate Drop Response that identifies abrupt cardiac slowing and responds by
    pacing the heart at an elevated rate, which may reduce the frequency of
    syncope (fainting) in patients with apparent cardio-inhibitory vasovagal
    syncope.^[6]^, [7]
  * Highupper tracking rate to provide pacing support at higher heart rates
    for active and younger patients.

This system is the latest addition to a growing number of Medtronic devices
which are designed for MRI access including the SynchroMed^® II programmable
drug infusion system available worldwide, and the SureScan^® neurostimulation
systems for the management of chronic pain which are available in Europe. In
addition, SureScan^® pacing systems - including Advisa MRI - are available
worldwide.

In collaboration with leading clinicians, researchers and scientists
worldwide, Medtronic offers the broadest range of innovative medical
technology for the interventional and surgical treatment of cardiovascular
disease and cardiac arrhythmias. The company strives to offer products and
services that deliver clinical and economic value to healthcare consumers and
providers around the world.

About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the
global leader in medical technology - alleviating pain, restoring health, and
extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as
those described in Medtronic's periodic reports on file with the Securities
and Exchange Commission. Actual results may differ materially from anticipated
results.

                                    -end-

-------------------------

[1] Medtronic data on file. November 27, 2012.

[2] Medtronic data on file. November 5, 2012.

[3] Kalin R and Stanton MS. Current clinical issues for MRI scanning of
pacemaker and defibrillator patients. PACE 2005;28:326-328.

[4] Gillis AM, Pürerfellner H, Israel CW, et al. Reduction ofunnecessary
ventricular pacing due to the Managed
Ventricular Pacing (MVP) mode in pacemaker patients: Benefit for both sinus
node disease (SND) and AV block (AVB) indications. Heart Rhythm. May
2005;2(5):S40. Abstract AB21-1.

[5] Rosenthal LS, Mester S, Rakovec P, et al. Factors influencing pacemaker
generator longevity: results from the complete automatic pacing threshold
utilization recorded in the CAPTURE Trial. Pacing Clin Electrophysiol. August
2010;33(8):1020-1030.

[6] Nordlander R, Hedman A, Phersson SK. Rate responsive pacing and exercise
capacity-a comment. PACE. 1989;12:749-751.

[7] Stone J, Crossley G. Current sensor technology for heart rate modulation
by artificial pacing. Clinical Electrophysiology Review. 1999;3:10-14.

 

Contacts:
Joey Lomicky
Public Relations
+1-763-526-2494

Jeff Warren
Investor Relations
+1-763-505-2696

For more information, visit www.jointhepacemakers.com/mri
Advisa DR MRI™ SureScan® video
Advisa DR MRI™ SureScan® image

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Medtronic, Inc. via Thomson Reuters ONE
HUG#1677482
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement